1
Country: Norway | Funding: $13.1M
Zelluna Immunotherapy is developing a unique and proprietary TCR-NK cell therapy platform for the treatment of cancer. The therapy utilizes human (donor) natural killer (NK) cells, driven by T-cell receptors (TCRs), which are administered to patients. TCRs provide precise targeting of cancer cells and enable NK cells to find and destroy cancer cells within the patient's body. Zelluna's development pipeline targets a combination of clinically or preclinically validated antigens expressed in a broad range of solid tumors, providing high potential for patient impact and a significant market opportunity. The company's undergoing clinical trials include the following indications: NSCLC, ovarian cancer, sarcoma, breast cancer, gastric cancer, lung cancer, pancreatic cancer, cervical cancer.
Zelluna Immunotherapy is developing a unique and proprietary TCR-NK cell therapy platform for the treatment of cancer. The therapy utilizes human (donor) natural killer (NK) cells, driven by T-cell receptors (TCRs), which are administered to patients. TCRs provide precise targeting of cancer cells and enable NK cells to find and destroy cancer cells within the patient's body. Zelluna's development pipeline targets a combination of clinically or preclinically validated antigens expressed in a broad range of solid tumors, providing high potential for patient impact and a significant market opportunity. The company's undergoing clinical trials include the following indications: NSCLC, ovarian cancer, sarcoma, breast cancer, gastric cancer, lung cancer, pancreatic cancer, cervical cancer.
2
Country: USA | Funding: $1.6B
IOVANCE Biotherapeutics develops personalized autologous cellular immunotherapies using tumor-infiltrating lymphocytes (TILs). A patient's natural TILs are collected and grown outside the body and then administered to the patient in a single dose. Unlike targeted cell therapies, which act on general antigen targets, IOVANCE TILs are engineered to act on specific neoantigens unique to the patient or tumor. IOVANCE's T-cell-based immunotherapy platform has potential application across multiple solid tumor types. The company has two approved drugs for the treatment of metastatic melanoma and metastatic kidney cancer. The company is also conducting clinical trials for the treatment of cervical cancer, NSCLC, endometrial cancer, and head and neck squamous cell carcinoma.
IOVANCE Biotherapeutics develops personalized autologous cellular immunotherapies using tumor-infiltrating lymphocytes (TILs). A patient's natural TILs are collected and grown outside the body and then administered to the patient in a single dose. Unlike targeted cell therapies, which act on general antigen targets, IOVANCE TILs are engineered to act on specific neoantigens unique to the patient or tumor. IOVANCE's T-cell-based immunotherapy platform has potential application across multiple solid tumor types. The company has two approved drugs for the treatment of metastatic melanoma and metastatic kidney cancer. The company is also conducting clinical trials for the treatment of cervical cancer, NSCLC, endometrial cancer, and head and neck squamous cell carcinoma.
3
Country: UK | Funding: $52M
Iksuda Therapeutics develops ADCs with enhanced tumor specificity. They incorporate tumor-specific, selective release and activation of payloads through mechanisms relevant to the target and tumor, thereby optimizing anticancer efficacy and improving patient safety. The company has also developed a new class of alkylating protein payloads, ProAlk. With their tailored properties to specific ADCs and broad applicability across various tumor types, Iksuda is currently developing a new ProAlk-ADC portfolio. The company's portfolio includes clinical trials against B-cell malignancies, breast cancer, gastric cancer, lung cancer, esophageal cancer, head and neck cancer, colorectal cancer and cervical cancer.
Iksuda Therapeutics develops ADCs with enhanced tumor specificity. They incorporate tumor-specific, selective release and activation of payloads through mechanisms relevant to the target and tumor, thereby optimizing anticancer efficacy and improving patient safety. The company has also developed a new class of alkylating protein payloads, ProAlk. With their tailored properties to specific ADCs and broad applicability across various tumor types, Iksuda is currently developing a new ProAlk-ADC portfolio. The company's portfolio includes clinical trials against B-cell malignancies, breast cancer, gastric cancer, lung cancer, esophageal cancer, head and neck cancer, colorectal cancer and cervical cancer.
4
Country: USA | Funding: $21.5M
Teal Health has created Teal Wand - device for at-home cervical cancer screening that is combined with virtual visit service for consultations on how to perform the screening and analyze the results. This is the first FDA-cleared device for at-home cervical cancer screening, providing the same accuracy as in-person clinic screening. After receiving the kit, patients collect a sample and mails it to the lab. Results can be viewed online in their account on the Teal portal. If further monitoring is needed, they can connect virtually with a Teal doctor to discuss next steps and coordinate a referral to a specialist.
Teal Health has created Teal Wand - device for at-home cervical cancer screening that is combined with virtual visit service for consultations on how to perform the screening and analyze the results. This is the first FDA-cleared device for at-home cervical cancer screening, providing the same accuracy as in-person clinic screening. After receiving the kit, patients collect a sample and mails it to the lab. Results can be viewed online in their account on the Teal portal. If further monitoring is needed, they can connect virtually with a Teal doctor to discuss next steps and coordinate a referral to a specialist.
5
Country: USA | Funding: $18.8M
4D Path develops QPOR platform, designed to directly measure and quantify cell cycle abnormalities and tumor microenvironment dynamics to predict patient response to therapy. It uses hematoxylin and eosin (H&E)-stained biopsy images to instantly uncover hidden data, enabling biomarker profiling and stratification. While the company initially focuses on breast cancer, it is actively developing products for ovarian cancer, cervical cytology, skin cancer, and, more broadly, immunotherapy for various cancer types.
4D Path develops QPOR platform, designed to directly measure and quantify cell cycle abnormalities and tumor microenvironment dynamics to predict patient response to therapy. It uses hematoxylin and eosin (H&E)-stained biopsy images to instantly uncover hidden data, enabling biomarker profiling and stratification. While the company initially focuses on breast cancer, it is actively developing products for ovarian cancer, cervical cytology, skin cancer, and, more broadly, immunotherapy for various cancer types.
6
Country: USA | Funding: $2.6M
Ananya Health is developing a medical device for the treatment of precancerous cervical conditions. Unlike current cryoablation treatments, which rely on a complex supply chain of expensive, bulky and difficult-to-transport gas cylinders or require the involvement of specialists such as obstetricians and gynecologists, Ananya produces a portable, easy-to-use, closed-loop cryoablation platform called the CRCL, which can be used in any clinic. The system is battery-powered and has wheels for portability. The company also claims the procedure costs 1/10th the cost of traditional gas-based cryoablation.
Ananya Health is developing a medical device for the treatment of precancerous cervical conditions. Unlike current cryoablation treatments, which rely on a complex supply chain of expensive, bulky and difficult-to-transport gas cylinders or require the involvement of specialists such as obstetricians and gynecologists, Ananya produces a portable, easy-to-use, closed-loop cryoablation platform called the CRCL, which can be used in any clinic. The system is battery-powered and has wheels for portability. The company also claims the procedure costs 1/10th the cost of traditional gas-based cryoablation.
7
Country: USA | Funding: $2.6M
Kovina Therapeutics is a preclinical biotechnology company developing a unique antiviral drug for the treatment of cancer and precancerous conditions associated with the human papillomavirus (HPV), including cervical, anal and oropharyngeal cancers. The company used powerful biotechnological tools to study the molecular mechanisms by which HPV proteins control infected cells and discovered new therapeutic molecules that block viral activity. The developed therapy should provide a non-surgical treatment option for HPV-induced cancer and precancerous conditions. This small-molecule drug specifically targets the HPV E6 oncogene, an oncogenic factor expressed in both precancerous and cancerous tissues. By inactivating HPV E6, the drug triggers apoptosis in infected cells without affecting healthy tissue.
Kovina Therapeutics is a preclinical biotechnology company developing a unique antiviral drug for the treatment of cancer and precancerous conditions associated with the human papillomavirus (HPV), including cervical, anal and oropharyngeal cancers. The company used powerful biotechnological tools to study the molecular mechanisms by which HPV proteins control infected cells and discovered new therapeutic molecules that block viral activity. The developed therapy should provide a non-surgical treatment option for HPV-induced cancer and precancerous conditions. This small-molecule drug specifically targets the HPV E6 oncogene, an oncogenic factor expressed in both precancerous and cancerous tissues. By inactivating HPV E6, the drug triggers apoptosis in infected cells without affecting healthy tissue.
8
Country: Canada
Wema is developing mobile app and online platform that provides cervical cancer screening to those in remote communities. It enables access to oncology services to those in need who currently have limited access to mainstream healthcare. The platform also offers high-quality provider and mentor training, real-time data collection and report writing. This allows rural healthcare workers to enhance their skills in conducting high-quality screening with real-time mentoring and diagnosis confirmation through a closed user group with colleagues and experts.
Wema is developing mobile app and online platform that provides cervical cancer screening to those in remote communities. It enables access to oncology services to those in need who currently have limited access to mainstream healthcare. The platform also offers high-quality provider and mentor training, real-time data collection and report writing. This allows rural healthcare workers to enhance their skills in conducting high-quality screening with real-time mentoring and diagnosis confirmation through a closed user group with colleagues and experts.
9
Country: India
Pragmatech Healthcare Solutions aims to make doorstep screening available for cervical cancer
Pragmatech Healthcare Solutions aims to make doorstep screening available for cervical cancer
